TransMedics Group, Inc., a leader in medical technology for organ transplant therapy, has announced new compensation terms as of May 21, 2025. The company has granted non-qualified stock options to purchase a total of 9,940 shares of its common stock and awarded 6,670 restricted stock units to 15 new employees. These grants, approved by the Compensation Committee, are designed as material inducements for the employees' entry into the company. The stock options are set at an exercise price of $121.31 per share and have a 10-year term. They will vest 25% on the first anniversary of the employment start date, with the remainder vesting monthly over the next three years. Meanwhile, the restricted stock units will vest in four equal installments on each of the first four anniversaries of the employment start date. Both the stock options and restricted stock units are subject to the terms of the TransMedics Group, Inc. Inducement Plan.